DiaMedica Therapeutics — Third Quarter 2026 Earnings Summary

DiaMedica Therapeutics reported a net loss of $11.3 million for the third quarter of 2026, with total cash, cash equivalents, and short-term investments standing at $34.9 million as of September 30, 2026. The company completed enrollment in the first two cohorts of its Phase 2 trial for early-onset fetal growth restriction and surpassed the 200-participant threshold for its ReMEDy2 acute ischemic stroke trial. Regulatory progress includes conditional authorization from the European Medicines Agency and Health Canada for early-onset preeclampsia studies, while the company continues to address FDA feedback regarding nonclinical reproductive toxicity data for a U.S. Investigational New Drug application. Management anticipates the ReMEDy2 interim analysis to be completed in the first quarter of 2027 and expects current cash reserves to fund operations through the fourth quarter of 2027.